{"record_key":"valenyx-therapeutics","identifier":"valenyx-therapeutics","external_key":null,"title":"Valenyx Therapeutics","summary":null,"url":"https://inventions.pitt.edu/startups/valenyx-therapeutics","json_url":"https://inventions.pitt.edu/startups/valenyx-therapeutics.json","object_key":"startups","description":"Valenyx Therapeutics is developing multispecific nanobody-based biologics for complex diseases, starting with osimertinib-resistant non-small cell lung cancer. Its platform combines proteomics-based discovery of serum-matured nanobodies with machine-learning candidate ranking and epitope-first engineering. [1]: https://valenyxtx.com/\nThe modular nanobody formats can be assembled into degrader-drug conjugates, T-cell engagers, antibody-oligonucleotide conjugates, and brain-shuttle biologics. The lead program, VT-001, is a tri-specific degrader-drug conjugate for non-small cell lung cancer and other solid tumors and is in IND-enabling studies. VT-002, a tri-specific dual-degrader conjugate, is in preclinical development, and VT-003, a broad-tissue single-domain antibody for CNS and muscle disease, is in discovery. [1]: https://valenyxtx.com/\nThe company is based in New York and is co-founded by CEO Md Kabir and scientific co-founders Jian Jin and Yi Shi, whose research on multispecific nanobody degraders underpins the platform. [2]: https://pubmed.ncbi.nlm.nih.gov/42146646/","attributes":[{"key":"website","label":"Website","values":["https://www.valenyxtx.com"]},{"key":"sector","label":"Sector","values":["Therapeutics"]},{"key":"therapeutic_areas","label":"Therapeutic Areas","values":["Oncology"]},{"key":"therapeutic_indications","label":"Therapeutic Indications","values":["Non-small cell lung cancer","Solid tumors"]},{"key":"funding_stage","label":"Funding Stage","values":["Seed"]},{"key":"founders","label":"Founders","values":["Md Kabir","Jian Jin","Yi Shi"]}],"related":[]}